secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001628280-25-018242
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal CMO/President of R&D Rebecca Taub steps down, becomes Senior Advisor through Dec 2025
--------------------------------------------------------------------------------

- Dr. Taub transitions from CMO and President of R&D to Senior Scientific and Medical Advisor effective April 21, 2025, through end of 2025.
- She will continue to serve on Madrigal's Board of Directors.
- Will receive base salary of $621,000 through Dec 31, 2025, and eligible for a 50% target bonus.
- Entered a Severance and Change of Control Agreement with standard severance: 12-month salary continuation, equity acceleration, and health benefits.
- No successor named; Taub will provide transition support and scientific guidance for MASH programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/0001628280-25-018242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025018242/mdgl-20250416.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-018242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer